MyDay MiSight 1 Day: What Independent Practices Need to Know About the New Myopia Management Lens

CooperVision has launched MyDay MiSight 1 day in the UK — and if your practice is not already offering myopia management to children, this is the moment to start taking it seriously.

Announced in January 2026 and formally launched at a national event in February, MyDay MiSight 1 day is a new daily disposable contact lens that combines two things CooperVision has separately proven to work: the silicone hydrogel material from their established MyDay lens family and the ActivControl Technology that has underpinned the original MiSight 1 day since its launch.

The result is not simply a product upgrade. For independent practices considering whether to build a myopia management service, it represents a materially better clinical and patient experience proposition than was previously available.

What the lens actually does.

MyDay MiSight 1 day is designed for children with myopia and does two jobs simultaneously. It corrects the child's vision and helps slow the rate at which myopia worsens over time.

The mechanism is the ActivControl Technology, which has been the foundation of the original MiSight 1-day lens for years. The lens design incorporates both vision correction zones and treatment zones. The correction zones do what any contact lens does — provide clear vision. The treatment zones create peripheral defocus that signals the eye to slow its elongation, which is the underlying mechanism of myopia progression.

Using measured and modelled data pooled across ages 8 to 17, myopia progression was slowed by approximately 50% with the ActivControl Technology. The same technology now sits in the MyDay MiSight 1-day lens.

What is new with this version is the material. The integration of silicone hydrogel is designed to deliver effective myopia control while maintaining the comfort, breathability and eye health benefits associated with silicone hydrogel daily wear. Silicone hydrogel transmits significantly more oxygen to the eye than standard hydrogel materials, which is relevant for a child wearing the lens for 12 or more hours during a school day, after-school activities, and evening homework.

The comfort data from CooperVision's crossover study is notable. A one-week study of 32 children aged 8 to 18 found that more children strongly preferred MyDay MiSight 1 day for comfort compared to the original lens, while confirming that the myopic defocus through the pupil was identical between the two lenses — meaning the treatment effect is preserved while comfort is improved.

The myopia management opportunity for independent practices.

The clinical case for myopia management is established. One in two children born today could have myopia by the age of 20. Myopia that is left unmanaged does not simply mean a child who needs stronger glasses each year. High myopia is associated with a significantly elevated risk of serious eye conditions in later life, including retinal detachment, glaucoma, and macular degeneration. Early intervention changes trajectories.

The commercial case for independent practices is equally compelling and considerably less discussed.

A child fitted with myopia management contact lenses is not a one-off transaction. They are in a patient relationship that spans years. The fitting, the follow-up appointments, the annual prescription reviews, the ongoing lens supply, the family relationships that bring parents and siblings through the door — myopia management, done properly, is one of the most effective patient retention and lifetime value strategies available to an independent practice.

It is also a service that independents can deliver with a depth of personal care and clinical continuity that high-volume corporate practices structurally struggle to replicate. Parents want to understand what is happening to their child's eyes. They want a practitioner who can explain the evidence clearly, who remembers the child's history, and who manages an ongoing treatment plan rather than just processing an appointment. They want continuity. They want trust. Those are precisely the conditions in which independent practices excel.

What does the improved material mean in practice?

The original MiSight 1 day has an established track record — it has been fitted on hundreds of thousands of children globally and is backed by the longest-running soft contact lens trial in children. Practitioners who have been fitting it know it works.

The practical challenge has been comfort and wearability for children new to contact lenses, especially when wearing them for extended periods. A child who finds their lenses uncomfortable by mid-afternoon is not wearing them consistently. A child who is not wearing them consistently is not receiving the full treatment benefit.

The silicone hydrogel material in MyDay MiSight 1 day directly addresses this. Higher oxygen transmissibility means healthier, more comfortable eyes at the end of the day. In the clinical study, 100% of children were satisfied with overall comfort, and 97% successfully handled the lenses. Those are not typical metrics for contact lens studies in children — and they matter practically, because a child who handles their lenses confidently and comfortably is more likely to wear them.

Getting started with myopia management in your practice.

CooperVision has done significant work to lower the barrier to entry for practitioners new to myopia management. There is online accreditation through the CooperVision Learning Academy, in-practice materials to support parent-child conversations, and a range of clinical resources, including an axial length calculator and a myopia vision simulator.

The accreditation is the right starting point. It covers the clinical rationale for myopia management, the fitting protocol and the conversation frameworks for speaking with parents, who may arrive with no prior awareness that managing a child's myopia progression is even possible.

That parent conversation is worth spending time on. A parent who brings their nine-year-old in for a sight test and discovers for the first time that myopia can be actively managed — not just corrected — is a parent who feels your practice has done something genuinely important for their child. That experience builds loyalty of a kind that no promotional offer can replicate.

Is this the right moment for your practice?

The launch of MyDay MiSight 1 day, with its improved comfort profile and the same proven treatment technology, makes this a good moment to evaluate whether myopia management is a service your practice should build or expand. The clinical evidence is solid. The patient need is growing — particularly relevant given Mintel's finding that 54% of UK consumers are already worried about the effects of screen time on eye health. This concern naturally extends to their children's eyes. The commercial case for an independent practice offering a personalised, continuity-based myopia management service is strong.

The accreditation is free. The conversation with CooperVision's practice support team costs nothing.

Product Details
Material / H20 content    stenfilcon A / 54%
UV blocker#    Yes
Replacement schedule    : Daily Replacement
Oxygen transmissibility    100 Dk/t (at -3.00D)
Thickness    0.08mm (@ -3.00DS)
Revenue carton size    30, 90
Base curve    8.4mm
Diameter    14.2mm
Sphere power    -0.25D to -6.00D (0.25D steps)
-6.50D to -10.00D (0.50D steps)

For further information on MyDay MiSight, visit CooperVision's practitioner page for 1 day. Accreditation is available through the CooperVision Learning Academy.